According to its latest filing with the US Securities and Exchange Commission (SEC), neuro-regulation technology company Neuraxis Inc. expects net sales to reach approximately $1.6 million for the first quarter ending March 31, 2026.

This financial forecast reflects the company's business development trends in the field of neuroscience. As a medical technology enterprise focused on innovative neuroregulation solutions, Neuraxis continues to advance the field of pain management through its patented technology platform. The quarterly revenue guidance disclosed by the company provides investors with an important reference for evaluating its business performance. In the context of the rapidly developing medical technology industry, this data will help the market better understand the company's growth trajectory and commercialization process.